Clinical Trials Browser

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02453620 2026-03-18

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1 Active not recruiting

57 enrolled

BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

NCT02496208 2026-03-18

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Phase 1 Active not recruiting

152 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03030378 2026-03-18

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03041688 2026-03-18

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Phase 1 Active not recruiting

58 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03321643 2026-03-18

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03983824 2026-03-18

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Active not recruiting

48 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04652960 2026-03-18

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Phase 1 Active not recruiting

38 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

NCT05353439 2026-03-18

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Phase 1 Active not recruiting

18 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05627245 2026-03-18

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Phase 1 Active not recruiting

48 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02160015 2026-03-17

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

12 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04708067 2026-03-05

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Phase 1 Active not recruiting

2 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05166616 2026-03-05

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

8 enrolled

Thoracic

Lung Neoplasms

NCT06203912 2026-03-05

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

3 enrolled

Plasma cell

Multiple Myeloma

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Phase 1 Active not recruiting

62 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Phase 1 Active not recruiting

34 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Phase 1 Active not recruiting

25 enrolled 14 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07031765 2025-12-18

Peds CHAMP1ON

Phase 1 Active not recruiting

12 enrolled

CNS

Astrocytoma, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma

NCT05564650 2025-12-08

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Phase 1 Active not recruiting

6 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05034627 2025-11-28

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Active not recruiting

15 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT01955499 2025-11-10

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Active not recruiting

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02862275 2025-10-23

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1 Active not recruiting

40 enrolled

Other hematologic neoplasm

Neoplasm Metastasis, Hematologic Neoplasms

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03939897 2025-09-24

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast

Breast Neoplasms

NCT05359211 2025-09-15

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1 Active not recruiting

28 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02879695 2025-08-15

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Phase 1 Active not recruiting

28 enrolled 16 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Phase 1 Active not recruiting

14 enrolled

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04514497 2025-03-06

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Phase 1 Active not recruiting

28 enrolled

EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04535401 2024-10-10

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase 1 Active not recruiting

10 enrolled

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms

NCT03278925 2024-08-02

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

Phase 1 Active not recruiting

14 enrolled

Fibrosis

Clinical Trials

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Peds CHAMP1ON

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

COD

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis